Pharmaceutical Business review

Promius Pharma launches new topical psoriasis drug

Scytera foam is said to be the first coal tar product in an aerosol foam vehicle to be launched into the psoriasis market.

Studies have demonstrated that coal tar treatment of psoriasis results in a reduction in the overproduction of skin cells, a reduction of itch and a promotion of healthy skin, the company said.

According to the company, Scytera foam’s technology allows the product to be spread easily and smoothly over large body areas. Along with the foam technology, Scytera foam uses a patented odor neutralizing system to minimize the coal tar odor.

Jeffrey Wasserstein, president of Promius, said: “We believe Scytera foam will be of significant benefit to dermatologists and their patients, enhancing the value and re-establishing the importance of coal tar for psoriasis treatment.”